Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 2019;14:667–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alhaj Moustafa M, et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015;29:2033–8.

Article  CAS  PubMed  Google Scholar 

Asosingh K, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood. 2004;103:3131–7.

Article  CAS  PubMed  Google Scholar 

Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–7.

Article  CAS  PubMed  Google Scholar 

Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones Myeloma. Lancet. 2003;361:489–91.

Article  PubMed  Google Scholar 

Carosella ED, Gregori S, Tronik-Le Roux D. HLA-G/LILRBs: a Cancer Immunotherapy Challenge. Trends Cancer. 2021;7:389–92.

Article  CAS  PubMed  Google Scholar 

Chumbley G, King A, Robertson K, Holmes N, Loke YW. Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol. 1994;155:312–22.

Article  CAS  PubMed  Google Scholar 

Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736–41.

Article  CAS  PubMed  Google Scholar 

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curtis VF, et al. Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in mucosal inflammatory responses. FASEB J. 2015;29:208–15.

Article  CAS  PubMed  Google Scholar 

Dawson DW, et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399–434.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41:827–35.

Article  PubMed  Google Scholar 

Dispenzieri A, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durie BG, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.

Article  CAS  PubMed  Google Scholar 

Fons P, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 2006;108:2608–15.

Article  CAS  PubMed  Google Scholar 

Garziera M, Scarabel L, Toffoli G. Hypoxic modulation of HLA-G expression through the metabolic sensor HIF-1 in Human Cancer cells. J Immunol Res. 2017;2017:4587520.

Article  PubMed  PubMed Central  Google Scholar 

Gladkova C, Maslen SL, Skehel JM, Komander D. Mechanism of parkin activation by PINK1. Nature. 2018;559:410–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greipp PR, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

Article  PubMed  Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

Article  CAS  PubMed  Google Scholar 

Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018;9:788.

Article  PubMed  Google Scholar 

Iwama K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur J Haematol. 2013;90:134–41.

Article  CAS  PubMed  Google Scholar 

Jakob C, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581–90.

Article  CAS  PubMed  Google Scholar 

Katzmann JA, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.

Article  CAS  PubMed  Google Scholar 

Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51:878–81.

Article  CAS  PubMed  Google Scholar 

Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: a New Immune Checkpoint in Cancer? Int J Mol Sci. 2020;21.

Kumar SK, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

Article  CAS  PubMed  Google Scholar 

Le Bouteiller P, et al. Soluble HLA-G and control of angiogenesis. J Reprod Immunol. 2007;76:17–22.

Article  PubMed  Google Scholar 

Lee MY, et al. Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoS ONE. 2009;4:e6913.

Article  PubMed  PubMed Central  Google Scholar 

Leleu X, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005;11:7297–303.

Article  CAS  PubMed  Google Scholar 

Li XJ, Zhang X, Lin A, Ruan YY, Yan WH. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol. 2012;73:946–9.

Article  CAS  PubMed  Google Scholar 

Lin Y, et al. Neddylation pathway alleviates chronic pancreatitis by reducing HIF1α-CCL5-dependent macrophage infiltration. Cell Death Dis. 2021;12:273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, et al. Parkin targets HIF-1alpha for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017;8:1823.

Article  PubMed